Alizyme - Renzapride - Ownership and Business Overview

Life ScienceCompany

Alizyme - Renzapride Ownership

Who owns Alizyme - Renzapride?

Alizyme - Renzapride is owned by EndoLogic. It was acquired on January 3, 2017.

Alizyme - Renzapride Business Overview

Where is Alizyme - Renzapride headquartered?

Alizyme - Renzapride is headquartered in Cambridge, United Kingdom.

What sector is Alizyme - Renzapride in?

Alizyme - Renzapride is a life science company.

Life Science M&A Summary in 2017

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2017. The largest life science acquisition in 2017 was Actelion - which was acquired by Johnson & Johnson for $30.0B.

Join Mergr to view all 248 acquisitions of life science companies in 2017, including 23 acquisitions by private equity firms, and 225 by strategics.

Alizyme plc - Renzapride

Cambridge, CB21 6GX
United Kingdom,

Alizyme plc - Renzapride is a 5-HT4 agonist and 5HT-3 antagonist, has been studied in more than 5,000 patients including one Phase 3 trial for the treatment of constipation-dominant irritable bowel syndrome (IBS-C). Renzapride demonstrated a small but statistically significant benefit in the Phase 3 study in IBS-C, however, Alizyme decided to not continue to pursue development of the drug for this indication.


 Subscribe to unlock this and 206,153
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for Alizyme - Renzapride

Life Science Companies , United Kingdom Companies